Marijn Aletta Gillissen

Title: Marijn Aletta Gillissen: Innovator in AML Therapeutics

Introduction

Marijn Aletta Gillissen is a notable inventor based in Amsterdam Zuidoost, Netherlands. He has made significant contributions to the field of therapeutics, particularly in the treatment of acute myeloid leukemia (AML). With a total of three patents to his name, Gillissen's work focuses on innovative solutions for combating myeloproliferative and lymphoproliferative disorders.

Latest Patents

Gillissen's latest patents include "Means and methods for counteracting myeloproliferative or lymphoproliferative disorders." This invention provides human AML-specific binding compounds that can bind to a cell surface component of AML cells. Additionally, it outlines therapeutic uses of these binding compounds against AML. Another significant patent is "AML antigens and uses thereof," which presents novel compounds comprising an antigen of AML cells and their various applications.

Career Highlights

Throughout his career, Marijn Aletta Gillissen has worked with several prominent companies in the biotherapeutics sector. Notably, he has been associated with Kling Biotherapeutics B.V. and Aimm Therapeutics B.V. His work in these organizations has contributed to advancements in therapeutic strategies for cancer treatment.

Collaborations

Gillissen has collaborated with esteemed colleagues, including Hergen Spits and Mette Deborah Hazenberg. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of AML therapeutics.

Conclusion

Marijn Aletta Gillissen stands out as a key figure in the development of innovative treatments for AML. His patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.